Company Directory

Benchtop super-resolution microscopes for single-molecule biological imaging

Oxford Nanoimaging (ONI) is an Oxford-based manufacturer of compact super-resolution fluorescence microscopes and consumable application kits for life science research. Its instruments enable researchers to visualise individual proteins, DNA, RNA, viruses, and nanoparticles at 20 nanometre resolution without specialist infrastructure. Applications include drug target validation, extracellular vesicle characterisation, antibody research, and spatial cell biology. Customers span academic institutions and pharmaceutical and biotechnology companies worldwide.

GCP-accredited oncology molecular diagnostics for clinical trials and research

The Cancer Molecular Diagnostics Laboratory is an ISO 15189-accredited molecular diagnostics facility within the University of Cambridge Department of Oncology, jointly funded by CRUK and NIHR. Operating to GCP and GCLP standards, it provides next-generation sequencing, circulating tumour DNA analysis, liquid biopsy workflows, and digital PCR services for oncology clinical trials and translational research. Services are available to clinical trials, independent research groups, and biotechnology companies as a site, central laboratory, and contract researcher.

Contract proteomics CRO and inventor of TMT isobaric mass tags

Proteome Sciences is a contract proteomics organisation and reagent manufacturer specialising in mass spectrometry-based protein biomarker discovery, validation, and targeted assay development. Its proprietary workflows serve pharmaceutical and biotechnology clients across drug discovery and clinical research. The company invented Tandem Mass Tag isobaric labelling reagents, now manufactured at its Frankfurt laboratory and distributed globally by Thermo Scientific under licence. Disease focus includes neurodegeneration, oncology, and stroke.

Non-invasive oral cancer screening using genomics and cell-free DNA

Wisdom Bioscience is a biotechnology company developing a non-invasive oral cancer screening platform that integrates next-generation sequencing and cell-free DNA analysis with saliva-based sample collection. The platform is designed to enable early detection of oral cancer through routine dental appointments, addressing a disease area where outcomes are strongly dependent on stage at diagnosis. The company is progressing through clinical validation ahead of commercial launch.

Solutions for genomics, diagnostics and precision medicine

QIAGEN is a global provider of sample preparation, molecular diagnostics, and genomics solutions for pharmaceutical, clinical, and research applications. Its UK headquarters at Citylabs 2.0, Manchester serves as the company's global centre of excellence for precision medicine and companion diagnostics, co-developing diagnostic tests with more than 25 pharmaceutical partners. The Manchester site maintains close partnerships with the University of Manchester and Manchester University NHS Foundation Trust.

Liquid biopsy NGS kits and genomic diagnostic services

Nonacus is a developer of next-generation sequencing reagents and library preparation kits for liquid biopsy and tissue-based genomic analysis. Its target enrichment and cell-free DNA workflow products support cancer detection, treatment stratification, and longitudinal monitoring. Through its clinical services division, Nonacus also provides ISO-accredited NGS diagnostic testing for hereditary cancer, tumour profiling, and prenatal applications, serving NHS trusts and private sector clients.

Infrared spectroscopy blood test for early multi-cancer detection

Dxcover is a clinical-stage biotechnology company developing a blood-based multi-cancer early detection test. Its platform applies infrared spectroscopy to a dried blood spot to capture a pan-omic biological signature spanning proteins, lipids, metabolites, and nucleic acids simultaneously. Machine learning algorithms interpret the resulting spectral data to identify cancer signatures at early stages, with proof-of-concept demonstrated across brain, colorectal, lung, and pancreatic cancers. The company is commercialising the test in the UK, EU, and US markets.

RNA sequencing liquid biopsy for cardiovascular and complex disease screening

MultiplAI Health is a Cambridge biotech developing a whole-blood RNA sequencing test for early screening of cardiovascular and other complex diseases. Its platform combines transcriptomic profiling of blood samples with a patented data transformation process and proprietary deep learning algorithms to generate precision risk assessments from a single blood draw. The technology is designed for universal, affordable, remote screening of asymptomatic individuals, enabling proactive cardiovascular risk management.

Integrated NGS assays for genomic profiling of haematological malignancies

Univ8 Genomics is a Belfast-based genomics diagnostics company developing targeted next-generation sequencing assays for the integrated clinical characterisation of haematological malignancies. Its assays enable simultaneous detection of clonal rearrangements, chromosomal translocations, copy number alterations and sequence variants from a single DNA input, replacing multiple parallel testing workflows. Products cover lymphoproliferative and myeloid disorders and have been validated in multicentre international studies across European clinical laboratories.

Proteomics and AI liquid biopsy for early lung cancer detection

Oxford Cancer Analytics is a biotechnology company developing blood-based diagnostic tests for early cancer detection using high-throughput circulating proteome analysis and machine learning. Its platform identifies protein biomarker signatures from blood samples to support clinical decision-making in lung disease, with initial applications in lung cancer and chronic obstructive pulmonary disease. The approach is designed to be minimally invasive, affordable, and deployable at population scale as an alternative to imaging and tissue biopsy.

Blood-based liquid biopsy for endothelial glycocalyx and microvascular health

Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The platform detects glycocalyx biomarker signatures from a blood sample using spectroscopic methods compatible with existing laboratory equipment, enabling non-invasive assessment of microvascular health for clinical prognostics and drug development research.

Molecular assay platform for genomic profiling in cancer diagnostics

Biofidelity is a Cambridge-based genomic technology company developing molecular assays for cancer biomarker detection in tissue and liquid biopsy samples. Its proprietary platform enables ultra-sensitive detection of somatic mutations at low variant allele fractions using a simplified four-step qPCR workflow, without requiring next-generation sequencing infrastructure. Products are designed for adoption in existing diagnostic laboratories globally. Current applications focus on non-small cell lung cancer biomarker profiling to guide targeted therapy selection and treatment monitoring.